|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Chest, Vol 91, 351-355, Copyright © 1987 by American College of Chest Physicians
ARTICLES |
J Escudero, J Navarro, A Padua, L Betancourt and G Nava
Enalapril was used to treat five patients with pulmonary arterial hypertension secondary to congenital cardiopathy, three with ventricular septal defect, one with arterial septal defect, and one with patent ductus arteriosus. The dose of enalapril was 20 mg/day. All patients underwent pretreatment and posttreatment cardiac catheterization. It was concluded that enalapril may be a useful drug in the treatment of pulmonary arterial hypertension secondary to congenital cardiopathy.
This article has been cited by other articles:
![]() |
K. OKADA, M. L. BERNSTEIN, W. ZHANG, D. P. SCHUSTER, and M. D. BOTNEY Angiotensin-converting Enzyme Inhibition Delays Pulmonary Vascular Neointimal Formation Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 939 - 950. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |